# To Evaluate the Safety and PK Characteristics After Co-administration of JW0104 and C2402 and Administration of JW0105

> **NCT06754943** · PHASE1 · COMPLETED · sponsor: **JW Pharmaceutical** · enrollment: 60 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Treatment A_Period 1
- **DRUG:** Treatment B_Period 2
- **DRUG:** Treatment A_Period 3
- **DRUG:** Treatment B_Period 4
- **DRUG:** Treatment B_Period 1
- **DRUG:** Treatment A_Period 2
- **DRUG:** Treatment B_Period 3
- **DRUG:** Treatment A_Period 4

## Key facts

- **NCT ID:** NCT06754943
- **Lead sponsor:** JW Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-17
- **Primary completion:** 2025-03-24
- **Final completion:** 2025-04-22
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06754943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06754943, "To Evaluate the Safety and PK Characteristics After Co-administration of JW0104 and C2402 and Administration of JW0105". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06754943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*